JP2012503203A5 - - Google Patents

Download PDF

Info

Publication number
JP2012503203A5
JP2012503203A5 JP2011528016A JP2011528016A JP2012503203A5 JP 2012503203 A5 JP2012503203 A5 JP 2012503203A5 JP 2011528016 A JP2011528016 A JP 2011528016A JP 2011528016 A JP2011528016 A JP 2011528016A JP 2012503203 A5 JP2012503203 A5 JP 2012503203A5
Authority
JP
Japan
Prior art keywords
composition
breast cancer
antibody
sample
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011528016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012503203A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/057578 external-priority patent/WO2010033866A2/en
Publication of JP2012503203A publication Critical patent/JP2012503203A/ja
Publication of JP2012503203A5 publication Critical patent/JP2012503203A5/ja
Pending legal-status Critical Current

Links

JP2011528016A 2008-09-19 2009-09-18 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体 Pending JP2012503203A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9854808P 2008-09-19 2008-09-19
US61/098,548 2008-09-19
PCT/US2009/057578 WO2010033866A2 (en) 2008-09-19 2009-09-18 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Publications (2)

Publication Number Publication Date
JP2012503203A JP2012503203A (ja) 2012-02-02
JP2012503203A5 true JP2012503203A5 (enExample) 2012-10-25

Family

ID=42040172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011528016A Pending JP2012503203A (ja) 2008-09-19 2009-09-18 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体

Country Status (6)

Country Link
US (3) US8486393B2 (enExample)
EP (1) EP2338055A4 (enExample)
JP (1) JP2012503203A (enExample)
AU (2) AU2009293007B2 (enExample)
CA (1) CA2737758C (enExample)
WO (1) WO2010033866A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010033866A2 (en) 2008-09-19 2010-03-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
US8318162B2 (en) 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
US20110243993A1 (en) * 2010-03-29 2011-10-06 Broo Kerstin S Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments
JP5451552B2 (ja) * 2010-08-09 2014-03-26 オリンパス株式会社 顕微鏡システム、標本観察方法およびプログラム
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
WO2015044218A1 (en) 2013-09-24 2015-04-02 Oncoinvent As Monoclonal antibody and derivatives
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US20160032007A1 (en) * 2014-04-28 2016-02-04 Duke University Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11091547B2 (en) 2014-11-12 2021-08-17 Memorial Sloan Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
US20170369588A1 (en) * 2014-12-23 2017-12-28 Universita' Degli Studi Di Parma Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US10881711B2 (en) 2015-04-06 2021-01-05 The General Hospital Corporation Anti-CSPG4 reagents and methods of treating cancer
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
ES2987957T3 (es) 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
BR112018013074A2 (en) 2015-12-30 2018-12-11 Novartis Ag immune effector cell therapies with enhanced efficacy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3117212A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
EP4138778A1 (en) 2020-04-22 2023-03-01 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
WO2023107538A2 (en) * 2021-12-07 2023-06-15 Regents Of The University Of Minnesota Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
JPWO2024106394A1 (enExample) * 2022-11-14 2024-05-23
EP4720059A1 (en) 2023-05-24 2026-04-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03501209A (ja) 1988-05-17 1991-03-22 フェロン、ソルダノ 抗ヒト高分子量メラノーマ関連抗原に対する抗イディオタイプ抗体
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1805214A2 (en) * 2004-10-20 2007-07-11 Friedrich-Alexander-Universität Erlangen-Nürnberg T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use
US20060223096A1 (en) 2005-03-25 2006-10-05 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
CN101405399A (zh) * 2006-03-16 2009-04-08 健康研究股份有限公司 抑制乳腺癌干细胞的生长和转移
WO2010033866A2 (en) * 2008-09-19 2010-03-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Similar Documents

Publication Publication Date Title
US12453780B2 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
US9409994B2 (en) High-affinity monoclonal antibodies to glypican-3 and use thereof
US9416190B2 (en) Mesothelin antibodies and methods for eliciting potent antitumor activity
US10052382B2 (en) Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
US20180214568A1 (en) Antibody-drug conjugates for targeting cd56-positive tumors
AU2020212534B2 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2010510809A5 (enExample)
JP2023547323A5 (enExample)
JP2020534830A5 (enExample)
JP2013506428A5 (enExample)
JP2016534735A5 (enExample)
WO2016022939A1 (en) Human monoclonal antibodies specific for 5t4 and methods of their use
WO2006039238A2 (en) Irta2 antibodies and methods of use
JP2014515600A5 (enExample)
EP3543259A2 (en) Antibody binding to carbonic anhydrase and use thereof
CN120248121A (zh) 包括fc突变和位点特异性缀合性质的抗体组合物
CN120383678A (zh) 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用
US20250313626A1 (en) Anti-cd200r1 antibodies
US20110171216A1 (en) Monoclonal antibodies specific for pancreatic neoplasia cells